Gilead Sciences acquires Ouro Medicines

Gilead Sciences has announced an agreement to acquire Ouro Medicines for up to $2.175 billion. This move aims to bolster Gilead's pipeline with a promising treatment for severe autoimmune diseases. The acquisition comprises an upfront payment of $1.675 billion and up to $500 million in milestone-dependent payments. This transaction will grant Gilead access to OM336, a clinical-stage bispecific T cell engager known as gamgertamig, which is under development for treating rare autoimmune conditions.

OM336 functions by redirecting autologous T cells against BCMA-expressing plasma cells, implicated in pathogenic autoantibody production. The drug has demonstrated early signs of efficacy in Phase I/II trials for autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). It has received FDA Fast Track and Orphan Drug designations for these conditions, with expectations to enter registrational studies by 2027. This acquisition underscores Gilead's strategic focus on expanding its inflammation portfolio with innovative therapies that aim to reset immune function in autoimmune diseases, according to Dietmar Berger, Gilead's Chief Medical Officer.

The acquisition also advances Gilead's collaboration with Galapagos, which is contemplating co-funding half of the deal's consideration and pre-registrational development costs, with a revenue-sharing agreement on net sales outside Greater China. Galapagos would receive 20% to 23% in royalties on net sales, while the agreement amends existing terms to enhance cash flexibility for Galapagos, including provisions for up to $150 million in share repurchases. This collaboration highlights the intertwined nature of investment and strategic resource sharing in the biotechnology sector.

Within the broader market context, the deal emphasizes the growing significance of targeted therapies aimed at autoimmunity. It positions Gilead competitively as it seeks to address unmet medical needs and leverage the differentiated approach of BCMA-targeted therapies. By integrating OM336 into its pipeline, Gilead follows a sector trend where larger pharmaceutical companies acquire innovative, clinical-stage products from smaller biotechs to bolster their therapeutic offerings and accelerate market entry.

The closing of this acquisition is contingent on standard regulatory approvals. Should these be met, OM336's progress will be closely watched as it transitions into later-stage clinical trials, potentially redefining treatment paradigms for autoimmune cytopenias. This transaction illustrates Gilead's broader strategy of investing in pioneering science intended to advance standards of care in complex immunological conditions.